Investors & News

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
17/Sep/2018
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018
06/Sep/2018
Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences
31/Aug/2018
Ascendis Pharma A/S Announces Upcoming Investor Presentations
29/Aug/2018
Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results
15/Aug/2018
Ascendis Pharma A/S Announces Second Quarter 2018 Financial Results and Business Update Conference Call on August 29
02/Aug/2018
Ascendis Pharma A/S Announces Participation in the 2018 Wedbush PacGrow Healthcare Conference
23/Jul/2018
Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting
06/Jun/2018
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism
30/May/2018
Ascendis Pharma A/S Reports First Quarter 2018 Financial Results
16/May/2018
Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30
08/May/2018
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP
07/May/2018
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
25/Apr/2018
Ascendis Pharma A/S Announces Upcoming Investor Presentations
02/Apr/2018
Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer
28/Mar/2018
Ascendis Pharma A/S Reports Full Year 2017 Financial Results
19/Mar/2018
Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018
16/Mar/2018
Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28
21/Feb/2018
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
20/Feb/2018
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
08/Feb/2018
Ascendis Pharma A/S Announces Participation in Leerink Partners 7th Annual Global Healthcare Conference
08/Jan/2018
Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH
03/Jan/2018
Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency